1. Hu X, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. Published 2021 Nov 26. 2. Salas A, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323-337.
3. Kevin L Winthrop, et al. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017 May;13(5):320.
4. Villarino AV, et al. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21-27.
5. Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18(11):545-551.
6. Xin P, Sun S, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.
7. Singh S, et al. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. Int Immunopharmacol. 2020;86:106731.
8. Banerjee S, et al. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects [published correction appears in Drugs. 2017 May;77(8):939] [published correction appears in Drugs. 2017 Jun 12;:]. Drugs. 2017;77(5):521-546.
9. Ciobanu DA, et al. JAK/STAT pathway in pathology of rheumatoid arthritis (Review). Exp Ther Med. 2020;20(4):3498-3503.
10. Kim YK, et al. Structural basis of intersubunit recognition in elongin BC-cullin 5-SOCS box ubiquitin-protein ligase complexes. Acta Crystallogr D Biol Crystallogr. 2013;69(Pt 8):1587-1597.